anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To develop an ultrasound semi-quantitative scoring system for the diagnosis and evaluation of gout and hyperuricemia.
METHODS: This study included 348 male patients: 81 patients with asymptomatic hyperuricemia, 182 patients with gout, and 85 patients with other arthritis. Clinical data were collected, ultrasound was detected, gout activity score was calculated to assess disease activity, and statistical analysis was performed.
RESULTS: Monosodium urate crystal deposition and subclinical arthritis were detected in 17 patients with asymptomatic hyperuricemia, with lesions concentrated in the metatarsophalangeal joint, ankle and peroneus-longus and brevis at rate of 91.8%. Gout was significantly higher than non-gouty arthritis in crystal scores (sum scores of double contour, aggregates, and tophi), but not in inflammation scores (sum scores of synovial hypertrophy, power Doppler [PD] activity, and tenosynovitis) and bone erosion. The optimal cut-off score for the diagnosis of gout by the crystal score was 2. The sensitivity, specificity, and AUC were 95.4%, 97.1%, and .965, respectively. Gout flare had higher inflammation scores than intercritical gout, while bone erosion scores were lower than intercritical gout. The active gout patients had higher ultrasound scores of tophi, bone erosion, and PD activity than the remission group (P < .001). The sensitivity, specificity and area under the receiver operating characteristic curve (AUC) for the identification with high disease activity gout by ultrasound semi-quantitative composite score were 76.2%, 84.2%, and .812, respectively.
CONCLUSION: Ultrasound helps early identification of patients at risk in asymptomatic hyperuricemia. Ultrasound semi-quantitative scoring allows for more objective and accurate assessment of gout lesions, correlates with disease activity, and helps in the diagnosis and assessment of gout.
Patients will be randomly divided into two groups, control and midazolam. The midazolam group will receive midazolam premedication in such a way that 7.5mg midazolam will be taken orally 30 minutes before the aspiration procedure. Because midazolam causes sedation, the woman will be monitored by midazolam after medical premedication to avoid possible complications and will not be allowed to get out of bed on her own for 30 minutes. After 30 min, all women, both test and control group, will begin aspiration under the control of transvaginal ultrasound of one or more mature follicles (TUGOR - transvaginal ultrasound guided oocyte retrieval) under short term general anesthesia.
1527638 Oil-based suspensions of niclosamide BAYER AG 14 Dec 1976 [20 Dec 1975] 52104/76 Heading A5B Orally administrable pharmaceutical or veterinary anthelmintic compositions consist of an oil-based suspension of niclosamide (2-hydroxy-5-2'-dichloro-4'-nitrobenzanilide) or a salt thereof, in which at least 50% of the particles of niclosamide or its salt are smaller than 2Á. The active compound may be anhydrous or contain water of crystallisation, and may be in the form of its piperazine (also anthelmintically active) salt. The composition may contain a surface-active agent (e.g. lecithin or a polyoxyethylated sorbitan monolaurate, or other anionic, cationic, ampholytic or non-ionic surfactants. Suitable oils are liquid paraffin and/or sesame oil. The compositions are prepared by grinding the niclosamide in the oil until the required particle size is reached, and optionally adding further oil and/or a surface active agent. The compositions are said to have improved storage stability and anthelmintic activity.
Joint range of motion of the subjects will be measured with a goniometer. Pain will be evaluated with the Visual Analogue Scale (VAS). In order to evaluate the upper extremity functions, the validity and reliability of the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire, conducted by Tülin Düger et al. The TAMPA Kinezophobia questionnaire, which has been validated and validated in 2011, will be used for kinesiophobia. The Burn-Specific Health Scale developed for burn patients will be used to evaluate the quality of life. The validity and reliability study of the questionnaire was conducted by Mehmet Adam et al.
PURPOSE:To obtain the subject composition in an industrially advantageous way by heat treatment of milky whey with the pH value adjusted to a specified level to produce a whey protein-associated product which is then put to membrane separation to recover kappa-caseinglycomacropeptide in the filtrate. CONSTITUTION:A milky whey with its pH value adjusted to >=5.0 is treated at >=80 deg.C to produce a whey protein-associated product, which is then eliminated by membrane separation using a precision filtration membrane <=0.5mum in pore size or an ultrafiltration membrane >=50000Da in fractionating molecular weight. The resulting filtrate is concentrated and/or desalinated to eliminate lactose and minerals and then dried to recover kappa-caseinglycomacropeptide-contg. powder, thus easily, efficiently obtaining the objective composition on an industrial scale at low cost. The above-mentioned heat treatment is pref. made at 80 deg.C for >=5min or at 120 deg.C for >=5sec.
Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
Administered 8 times daily at approximately 50 minutes intervals (between session end and start) for 5 days. Each session will deliver 1800 pulses of active iTBS (bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz, with a duty cycle of 2 seconds on, 8 seconds off, over 60 cycles / \~10 minutes) at a target intensity of 110% of the subject's resting motor threshold.
Acute cholangitis is an infection of the biliary tract which is managed with biliary drainage and antibiotic therapy (ABT). Currently the international Tokyo Guidelines 2018 (TG18) recommend 4 to 7 days of ABT after source control. The national SWAB guideline of 2020 suggests a course of one to 3 days after biliary drainage. There are no randomized studies to guide the duration of ABT for acute cholangitis. Our recent retrospective study in the Netherlands showed that a short course of ABT seems safe and more evidence is available showing that other bacterial infections, including abdominal and bloodstream infections, can be treated with a short antibiotic course than previously assumed. Hence, the hypothesis is that a very short-course of ABT for acute cholangitis is non-inferior to a course of 4 to 7 days after adequate biliary drainage.

This study is designed as a multicenter non-inferiority randomized controlled trial. Patients will be randomly assigned to the intervention group (one day of antibiotic therapy after ERCP) or the comparator group (4 to 7 days of antibiotic therapy after ERCP).
Stroke is an acute neurologic dysfunction of vascular origin with sudden or at least rapid occurrence of symptoms and signs corresponding to the involvement of focal areas in the brain.The two main types of stroke are ischemic and hemorrhagic.Thrombosis can form in the extracranial and intracranial arteries when the intima is roughened and plaque forms along the injured vessel.The endothelial injury permits platelets to adhere and aggregate, then coagulation is activated and thrombus develops at site of plaque.Blood flow through the extracranial and intracranial systems decreases, and the collateral circulation maintains function. When the compensatory mechanism of collateral circulation fails, perfusion is compromised, leading to decreased perfusion and cell death. Stroke is the third leading cause of death in the United States. Many people die each year from stroke in the United States.Stroke is the leading cause of serious, long-term disability in the United States. Nearly one fourth of strokes occur in people under the age of 65.High blood pressure is the most important risk factor for stroke. Intravenous recombinant tissue-type plasminogen activator is the only Food and Drug Administration approved treatment for acute ischemic stroke. Mechanical thrombectomy improves clinical outcomes in patients with acute ischemic stroke caused by a large vessel occlusion.There is no apparent benefit of intravenous thrombolysis to patients with ischemic stroke undergoing mechanical thrombectomy. The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset.
A detection method of alcohol substances and metallic mercury in white spirit relates to the detection field. The invention aims to provide a method for identifying and quantitatively detecting alcohol substances such as methanol and the like, metallic mercury and the content thereof in white spirit by adopting amoxicillin carbon nanodots. According to the invention, amoxicillin is taken as the only precursor, and the amoxicillin carbon nanodots are rapidly synthesized by adopting a one-step microwave method. The amoxicillin carbon nano-dots retain partial structure and antibacterial property of amoxicillin, and have low biotoxicity, good antibacterial activity and good stability. Meanwhile, the amoxicillin carbon nano-dot can rapidly and simply realize mercury detection through fluorescence intensity change, and the detection limit is 1.07 mu M. The method can also qualitatively and quantitatively distinguish the compounds and the content of the monohydric alcohol and the ortho-dihydric alcohol, and particularly identify and quantitatively detect the methanol and the content thereof in the ethanol in a certain range. The multiple functions of the antibacterial amoxicillin carbon nano-dot have good application prospects in the aspects of antibacterial and mercury, methanol and other alcohol detection.
A non-randomized, prospective study of up to 150 subjects with asthma. Patients will perform eNO testing with the Apieron INSIGHT(tm) eNO system and the NIOX eNO system at the physician's office/clinic after a short demonstration and training by a healthcare professional trained in the use of the devices. Exhaled NO testing involves inhaling to lung capacity, and then performing a controlled exhalation into a mouthpiece connected to each of the Apieron INSIGHT(tm) and NIOX systems. Patients will perform an eNO measurement with the Apieron INSIGHT(tm) system and with the FDA cleared NIOX system for the accuracy portion of the study. Patients will perform 2 sequential eNO measurements on each system for the precision part of the study. Subjects that measure eNO values over 100 ppb will be asked to repeat 2 sequential eNO measurements on each system.
PROBLEM TO BE SOLVED: To provide a method for activating various immune cells ex vivo to enhance their functions and a method for evaluating multi-functionality of cells related to immunity.SOLUTION: According to the present invention, there is provided a method for enhancing the multi-functionality of Immune cells, the method comprising treating collected immune cells with a biguanide-based antidiabetic drug selected from metformin, phenformin, and buformin in vivo to increase the number of CD8T cells having high IL-2, TNFα and IFNγ producing abilities. There is also provided a method for enhancing the functions of immune cells. Here, the immune cells are selected from CD8T cells, CDT cells, NK cells, γδT cells, NKT cells, B cells, and bone marrow cells. There is also provided a method for treating and/or preventing a disease associated with immune abnormality using immune cells with enhanced functions as an active ingredient. There is further provided a method for evaluating the multi-functionality of immune cells. Here, immune cells treated with a biguanide-based antidiabetic drug selected from metformin, phenformin, and buformin are compared with control immune cells not treated with biguanide-based antidiabetic drug with respect to their multifunctionality.SELECTED DRAWING: None
<P>PROBLEM TO BE SOLVED: To provide an oily thickened gel-like composition presenting extremely low skin irritancy, rich in oily component, and suitable for cleansing cosmetics, humectant cosmetics and the like, to provide a method for preparing an emulsified composition by using the oily thickened gel-like composition, to provide the emulsified composition, and to provide a cosmetic comprising the emulsified composition or the oily thickened gel-like composition.  <P>SOLUTION: This oily thickened gel-like composition comprises an anionic surfactant having lipopeptide structure, water and/or a polyhydric alcohol and an oily component. The emulsified composition is obtained by incorporating the above composition with water. The method for preparing the emulsified composition is provided. The cosmetic comprises the oily thickened gel-like composition or the emulsified composition.  <P>COPYRIGHT: (C)2003,JPO
The present invention relates to topical compositions comprising a corticosteroid and at least one penetration enhancing agent, wherein the composition is substantially free of propylene glycol, for prophylaxis, amelioration, or treatment of a skin condition. Dermatological corticosteroids, in particular clobetasol propionate in topical preparations face multiple problems, such as delivery efficiency, stability, and tolerability, in particular with respect to excipients that would not cause irritation. For instance, the currently available topical compositions comprising clobetasol appear to show adverse effects on the endocrine system. Accordingly, there is a long felt need to develop an effective topical clobetasol composition with reduced concentration of active, but having an effect comparable to that obtainable with conventional topical clobetasol propionate compositions. Further it is desirable to have a clobetasol propionate composition with improved absorption without causing any skin irritation. Thus, the present invention provides a topical composition comprising between 0.015% and 0.035% (w/w) clobetasol, and at least one penetrating enhancing agent selected from the group consisting of polyols, glycols, ethers, glycol ethers, esters, sulfoxides, fatty acids, fatty acid esters, fatty alcohols, essential oils, terpenes, terpenoids, PEGylated fatty acids, PEGylated fatty acid esters, PEGylated fatty alcohols, and mixtures thereof, and at least one pharmaceutically acceptable excipient, wherein the penetration enhancing agent is substantially free of polypropylene glycol, wherein the composition has a viscosity of from about 0.1 cP to about 500 cP when measured by Brookfield viscometer Cap 2000+ with spindle no. 1 at 530 rpm at 25 °C.
Method comprises adding to the tablet mixture 3-20% w/w of Mg-silicate as hardener, a hydrogenated vegetable oil as lubricant and a modified starch as excipient. The mix forms hard, non-friable tablets which may be coated, opt. in liquid media. They are resistant to mechanical shock and may be marked on the surface. The Mg-silicate used is of formula : nMgO, n1SiO2, xH2O where n is about 2, n' is about 3 and x is on av. about 5.
PURPOSE: To obtain a kit comprising an anti-human malignant tumor blood serum and a formulation containing a human granular leukocyte colony stimulating factor as an active component and extremely stimulating malignant tumor- killing action of human matured granular leukocyte, especially neutrophilic leukocyte with slight adverse effect. CONSTITUTION: In this kit, an anti-human malignant tumor blood serum is combined with a formulation of a human granular leukocyte colony stimulating factor (human G-CSF) as an active component. As a malignant tumor to be a curing object, e.g. a malignant melanoma is exemplified. As the human G-CSF, a human G-CSF-containing polypeptide obtained by a gene-recombination and expressed by an amino acid sequence of the formula ((m) and (n) are each 0 or 1), etc., is preferable. A formulation containing 0.5-200μg human G-CSF is preferably administrated to one adult at 1-7 times in a week. The anti- malignant tumor blood serum is usually administrated to one adult in an amount of 0.1-5cc.  The anti-malignant tumor blood serum is preferably administrated by injection before about 1hr at increasing of the granular leukocyte to reach a peak by administration of the human G-CSF-containing formulation.
In patients who have received previous antituberculous therapy, administer ethambutol hydrochloride 25 mg per kilogram (11 mg per pound) of body weight, as a single oral dose once every 24 hours. Concurrently administer at least one other antituberculous drug to which the organisms have been demonstrated to be susceptible by appropriate in vitro tests. Suitable drugs usually consist of those not previously used in the treatment of the patient. After 60 days of ethambutol hydrochloride administration, decrease the dose to 15 mg per kilogram (7 mg per pound) of body weight, and administer as a single oral dose once every 24 hours.

During the period when a patient is on a daily dose of 25 mg/kg, monthly eye examinations are advised.

See Table for easy selection of proper weight-dose tablet(s).
PURPOSE:To highly raise the solubility of a tissue plasminogen activator (t-PA) by using a solvent system containing arginine or an acid-added salt thereof. CONSTITUTION:The concentration of a t-PA in its aqueous solution is raised to >=0.2mg/ml by incorporating the solution with 1-500 (pref. 5-200)mM of arginine or an acid-added salt thereof. It is more preferable that 0.02-2.0 (pref. 0.1-1.0) M of a neutral salt, esp. sodium chloride, be made to coexist in said solution. With the above method, an aqueous solution of t-PA at high concentrations can be prepared; thereby, a small volume of vessel for pharmaceuticals (e.g. a vial, ampule) can be packed with a relatively large quantity of t-PA, enabling a therapeutically effective thrombolytic agent to be manufactured. And, when an arginine-contg. solvent is used in the purification process for t-PA such as dialysis, filtration or chromatography (esp. gel chromatography), t-PA can be purified in its highly concentrated state, resulting in its efficient purification.
Methylglyoxal (MG) is considered a classical biomarker of diabetes mellitus and its comorbidities. However, a role for this compound in exacerbated immune responses, such as septicemia, is being increasingly observed and requires clarification, particularly in the context of neuroinflammatory responses. Herein, we used two different approaches (in vivo and acute hippocampal slice models) to investigate MG as a biomarker of neuroinflammation and the neuroimmunometabolic shift to glycolysis in lipopolysaccharide (LPS) inflammation models. Our data reinforce the hypothesis that LPS-induced neuroinflammation stimulates the cerebral innate immune response by increasing IL-1β, a classical pro-inflammatory cytokine, and the astrocyte reactive response, via elevating S100B secretion and GFAP levels. Acute neuroinflammation promotes an early neuroimmunometabolic shift to glycolysis by elevating glucose uptake, lactate release, PFK1, and PK activities. We observed high serum and cerebral MG levels, in association with a reduction in glyoxalase 1 detoxification activity, and a close correlation between serum and hippocampus MG levels with the systemic and neuroinflammatory responses to LPS. Findings strongly suggest a role for MG in immune responses.
Biologically active complex comprises a combination of (i) biological principle active at mitochondrial level deoxyribonucleic acid, which is (a) amino acids, e.g. serine, cysteine, isoleucine, asparagine or threonine-containing pentapeptide, (b) a soy protein hydrolyzate or (c) mixture of (a) and (b) with (ii) biological principle active at nuclear level deoxyribonucleic acid, which is (d) teprenone and (e) fine Myrtus communisplant extract or (f) mixtures of (c) and (d). An independent claim is also included for a cosmetic anti-aging composition comprising the biologically active complex and a carrier. ACTIVITY : Dermatological. The ability of biologically active complex having dermatological activity was tested in-vivo on 20 volunteers of age group around 43-69 by applying the emulsion with 4% of active agent against a control around the eye and checking the reduction of wrinkles. The result showed (after 56 days) that 39% of the total wrinkle area, 36% of total wrinkle length and 30% of number of wrinkles, around which the active complex was applied was reduced compared to the area around which the control was applied. MECHANISM OF ACTION : None given.
In eight controlled trials of patients with AFIB/AFL and other supraventricular arrhythmias (N=659) there were four cases of Torsade de Pointes reported (0.6%) during the controlled phase of treatment with Sotalol AF. The incidence of Torsade de Pointes was significantly lower in those patients receiving total daily doses of 320 mg or less (0.3%), as summarized in Table 5 below. Both patients who had Torsade de Pointes in the group receiving >320 mg/day were receiving 640 mg/day. In the group receiving ≤320 mg daily, one case of TdP occurred at a daily dose of 320 mg on day 4 of treatment and one case occurred on a daily dose of 160 mg on day 1 of treatment.

Pointes

Prolongation of the QT interval is dose related, increasing from baseline an average of 25, 40, and 50 msec in the 80, 120, and 160 mg groups, respectively, in the clinical dose-response study. In this clinical trial Sotalol AF treatment was not initiated if the QT interval was greater than 450 msec and during therapy the dose was reduced or discontinued if the QT interval was ≥520 msec.

Experience in patients with ventricular arrhythmias is also pertinent to the risk of Torsade de Pointes in patients with AFIB/AFL (see below).
The present invention involves the isolation of plant based CNCs from the leaves of S. cumini. For the formation of NCs, a novel greener approach using S. cumini LE as reducing agent for in situ impregnation of AgNPs as fillers into CNCs as matrix is reported. The silver nitrate solution in three different concentrations of 1 mM, 5 mM and 10 mM was used to form NCs where AgNPs have been incorporated into CNCs matrix. The CNCs and NCs were characterized using SEM, TEM, XRD, Zeta potential, FT-IR, and UV-Vis spectroscopy. NCs developed in the form of film and ointment showed strong antimicrobial activity against both gram negative and gram positive bacteria. NCs wound dressing is capable of regulating wound exudates and providing moisture to wound responsible for faster healing of acute wounds. The observations from histopathological and biochemical assays confirmed that NCs enhance healing because of lesser inflammation, rapid angiogenesis, early collagen formation and enhanced rate of reepithelization.
Penetrating neck injuries are not uncommon, while penetrated foreign bodies involving the larynx are rare, which can be critical and challenging even for experienced physicians. We presented a case of a 64-year-old man with a piece of grinder blade penetrating through the subglottic region, visiting our outpatient department with hoarseness persisting for 3 weeks. The flexible fiberoptic laryngoscope, CT and direct laryngoscope were used to establish the right diagnosis. A cervical incision over the prior scar region was performed to remove the foreign body from the laryngeal box. Clinically, laryngotracheal injuries could lead to severe crisis without proper and prompt treatment. As to penetrated foreign bodies involving the larynx, a proper airway management and surgical approach are crucial for minimizing the morbidity and mortality. An accurate localization and preoperative planning is on the other hand indispensable to a successful removal and recovery.